← Back to Search

Supportive Care for Lung Cancer

N/A

Recruiting

Led By Carolyn J Presley

Research Sponsored by Ohio State University Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosed with an advanced lung cancer: unresectable stage IIIA, IIIB, or stage IV non-small cell lung cancer (NSCLC) or extensive stage small cell lung cancer (SCLC)

Age >= 60 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 month

Awards & highlights

Study Summary

This trial is testing whether a supportive care intervention can improve physical and emotional wellbeing in patients with lung cancer. The intervention includes physical therapy and relaxation interventions.

Who is the study for?

This trial is for adults aged 60 or older with advanced lung cancer (stage IIIA, IIIB, or IV non-small cell lung cancer or extensive stage small cell lung cancer). They must be able to understand and sign a consent form, have a certain level of physical function, and plan to receive treatment at the Ohio State University Comprehensive Cancer Center. Prisoners are not eligible.Check my eligibility

What is being tested?

The ROAR-LCT trial is testing a supportive care intervention aimed at improving physical and emotional wellbeing in patients undergoing treatment for advanced lung cancer. It includes questionnaires, quality-of-life assessments, relaxation therapy like muscle relaxation exercises, best practice guidelines adherence, and an exercise program managed by physical therapists.See study design

What are the potential side effects?

Since this trial focuses on supportive care rather than drug treatments, side effects may include discomfort from exercise or relaxation therapy sessions. However, these interventions are generally considered safe and aim to improve symptoms and quality of life.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My lung cancer is at an advanced stage and cannot be surgically removed.

Select...

I am 60 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 month

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 month

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Amount and duration of therapy that participants were able to complete

Preliminary effect on functional status

Retention

+1 more

Secondary outcome measures

Incidence and severity of toxicity

Physical Endurance

Physical capability

+3 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Arm I (ROAR-LCT intervention)Experimental Treatment5 Interventions

Patients receive ROAR-LCT intervention weekly for 12 weeks consisting of physical therapy visits and an exercise intervention. Patients also undergo progressive muscles relaxation exercises over 20 minutes for 12 weeks.

Group II: Arm II (standard of care)Active Control3 Interventions

Patients receive standard of care for 12 weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Physical Therapy

2020

Completed Phase 4

~1460

Relaxation Therapy

2007

Completed Phase 3

~1160

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH

1,671 Previous Clinical Trials

28,016,963 Total Patients Enrolled

Ohio State University Comprehensive Cancer CenterLead Sponsor

320 Previous Clinical Trials

290,067 Total Patients Enrolled

Carolyn J PresleyPrincipal InvestigatorOhio State University Comprehensive Cancer Center

Media Library

Physical Therapy Clinical Trial Eligibility Overview. Trial Name: NCT05339022 — N/A

Non-Small Cell Lung Cancer Research Study Groups: Arm I (ROAR-LCT intervention), Arm II (standard of care)

Non-Small Cell Lung Cancer Clinical Trial 2023: Physical Therapy Highlights & Side Effects. Trial Name: NCT05339022 — N/A

Physical Therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05339022 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What outcome is being sought through this research endeavor?

"This trial's primary aim is to measure adherence over a 6 Month period. Secondary objectives include assessing the severity and incidence of toxicity through CTCAE V5, evaluating physical endurance with a 2-6 minute walk test, and using GAD-7 surveys to detect psychological symptoms in participants."

Answered by AI

How many individuals are being examined in this clinical trial?

"Correct. According to clinicaltrials.gov, the research project which was first published on April 14th 2022 is actively enrolling patients at this time. The team aims to recruit 100 individuals from one medical facility."

Answered by AI

Are there any available slots for participants in this clinical trial?

"Affirmative, according to clinicaltrials.gov information this research project is still open for recruitment and began on April 14th 2022. The last time the trial was updated was August 30th 2022 with a current requirement of 100 participants across 1 center."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial

Carolyn Presley 2022. "Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05339022.